Surgical Oncology, Tata Memorial Centre & Homi Bhabha National Institute, Mumbai, India.
Orthopaedic Oncology, Tata Memorial Centre & Homi Bhabha National Institute, Mumbai, India.
J Hand Surg Eur Vol. 2021 Sep;46(7):774-780. doi: 10.1177/17531934211007820. Epub 2021 Apr 22.
The purpose of this study was to report the incidence of giant cell tumour of the hand bones in an Asian population, document treatment options and report outcomes of treatment. Of 698 giant cell tumours of bone that underwent surgery between January 2011 and December 2020 at our institute, only 22 (3%) were in the hand. Fourteen occurred in the metacarpals, eight in the phalanges. Fifteen were primary tumours and seven had recurrent disease. Twenty lesions had an associated soft tissue component. Two patients treated for primary disease and one who had been treated for recurrence had local recurrence. Recurrence occurred in two of nine patients treated with curettage, one of three with resection and none of five with ray or digit amputation. Both curettage and resection/amputation are acceptable treatment options for the rare condition of giant cell tumour of bone in the hand, with a need to individualize treatment decisions based on the site and extent of disease to minimize treatment morbidity while maximizing disease control. IV.
本研究旨在报告亚洲人群手部骨巨细胞瘤的发病率,记录治疗方案并报告治疗结果。在我们研究所,2011 年 1 月至 2020 年 12 月期间,698 例骨巨细胞瘤中仅有 22 例(3%)发生在手部,其中 14 例发生在掌骨,8 例发生在指骨。15 例为原发性肿瘤,7 例为复发性疾病。20 例病变伴有软组织成分。2 例原发性疾病患者和 1 例复发性疾病患者局部复发。2 例接受刮除术治疗的患者、1 例接受切除术治疗的患者和 5 例接受射线或指(趾)截断术治疗的患者均出现复发。刮除术和切除术/截肢术均为手部骨巨细胞瘤这一罕见疾病的可接受治疗方案,需要根据疾病的部位和范围个体化治疗决策,以最小化治疗发病率,同时最大限度地控制疾病。IV。